Objectives: The occurrence of lamivudine resistance is often associated with the clinical breakthrough, which is characterised by the reappearance of hepatitis B virus (HBV) DNA in serum and the elevation of aminotransferases. We evaluated the efficacy of alpha interferon for clinical breakthrough in patients receiving lamivudine therapy
BACKGROUND: There is a paucity of data on the long-term efficacy of combination lamivudine and adefo...
Background and Aims : Non-response to interferon (IFN) monotherapy is a major therapeutic problem in...
WOS: 000177028800012PubMed ID: 12139566Background : Lamivudine is a new alternative therapeutic agen...
PubMed ID: 15048595Background/aims: The most important problem of the lamivudine therapy is the freq...
textabstractBACKGROUND, AIM, AND METHODS: Alpha interferon is the generally approved therapy ...
Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive ...
Aim: To investigate the safety and efficacy of long-term combination therapy with alpha interferon a...
Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive ...
The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to ...
Therapy of chronic hepatitis B remains a major clinical challenge. During many years interferon alph...
The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting mai...
Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) antibody seroconversion is ...
OBJECTIVE: To assess the efficacy of lamivudine treatment on hepatitis B e antigen (HBeAg) and/or h...
Chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus (HCV) is still a major problem...
Background and study aims : To investigate the efficacy of the combined therapy of lamivudine (LAM) ...
BACKGROUND: There is a paucity of data on the long-term efficacy of combination lamivudine and adefo...
Background and Aims : Non-response to interferon (IFN) monotherapy is a major therapeutic problem in...
WOS: 000177028800012PubMed ID: 12139566Background : Lamivudine is a new alternative therapeutic agen...
PubMed ID: 15048595Background/aims: The most important problem of the lamivudine therapy is the freq...
textabstractBACKGROUND, AIM, AND METHODS: Alpha interferon is the generally approved therapy ...
Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive ...
Aim: To investigate the safety and efficacy of long-term combination therapy with alpha interferon a...
Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive ...
The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to ...
Therapy of chronic hepatitis B remains a major clinical challenge. During many years interferon alph...
The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting mai...
Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) antibody seroconversion is ...
OBJECTIVE: To assess the efficacy of lamivudine treatment on hepatitis B e antigen (HBeAg) and/or h...
Chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus (HCV) is still a major problem...
Background and study aims : To investigate the efficacy of the combined therapy of lamivudine (LAM) ...
BACKGROUND: There is a paucity of data on the long-term efficacy of combination lamivudine and adefo...
Background and Aims : Non-response to interferon (IFN) monotherapy is a major therapeutic problem in...
WOS: 000177028800012PubMed ID: 12139566Background : Lamivudine is a new alternative therapeutic agen...